Celgene

REBLOZYL

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Celgene

Reblozyl HCPCS:

J0896

HCPCS Code Descriptor:

Injection, luspatercept-aamt, 0.25 mg

Category:

J Code

Reblozyl NDCs:

59572-0711-01, 59572-0775-01

Primary Type:

Anti-Anemia

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Subcutaneous

Reblozyl CPT Codes:

Potential CPT administration codes for Reblozyl can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Reblozyl:

REBLOZYL is an Anti-Anemia drug manufactured by Celgene and administered via the Subcutaneous route of administration. The J Code: J0896 is aligned to the drug REBLOZYL.

ACCESS PRICING AND MORE BY REGISTERING

J0896 Added Date:

July 1, 2020

J0896 Effective Date:

July 1, 2020

J0896 Termination Date:

HCPCS Active

Reblozyl billing and coding information can be found through Celgene at the link below:
Reblozyl patient assistance information can be found through Bristol Myers Squibb Access Support at the URL: https://www.bmsaccesssupport.bmscustomerconnect.com/patient
REBLOZYL prescribing information can be found at the link below:
Information regarding REBLOZYL’s side effects can be found at MedlinePlus